Bromocriptine: Old drug, new formulation and new indication

Diabetes, Obesity and Metabolism

Volumn 12, Issue 12, 2010, Pages 1048-1057

  Holt, Richard I G ^a   Barnett, A H ^b   Bailey, C J ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antidiabetes drug; Bromocriptine; Circadian rhythms; Clinical trials; Diabetes mellitus; Drug mechanism; Glycaemic control; Treatment

Indexed keywords

ANTIDIABETIC AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CYCLOSET; CYCLOSPORIN; DOPAMINE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; PLACEBO; QUINAGOLIDE; SEROTONIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; GALACTORRHEA; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERPROLACTINEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOTHALAMUS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL FIBROSIS; REVIEW; VALVULAR HEART DISEASE;

EID: 77958579813     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01304.x     Document Type: Review

References (58)

1. International Diabetes Federation. IDF Diabetes Atlas, 4th edn. Brussels, Belgium: International Diabetes Federation, 2009.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Barnett AH, Chapman C, Gailer K, Hayter CJ. Effect of bromocriptine on maturity onset diabetes. Postgrad Med J 1980; 56: 11-14.
4. Cincotta AH, Meier AH, Cincotta JM. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-1707.
5. Scranton R, Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010; 11: 269-279.
6. Burns RS, Calne DB. Disposition of dopaminergic ergot compounds following oral administration. In: Calne DB, Horowski R, McDonald RJ eds. Lisuride and Other Dopamine Agonists. New York: Raven Press, 1983; 153-160.
7. Maurer G, Schreier E, Delaborde S, Nufer R, Shukla AP. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983; 8: 51-62.
8. Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694-697.
9. Bernard C. Chiens rendus diabetiques. Com Rend Soc Biol (Paris) 1850; 1: 60.
10. Meier AH, Cincotta A. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996; 4: 464-487.
11. Lam TK, Pocai A, Gutierrez-Juarez R et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005; 11: 320-327.
12. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-572.
13. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003; 9: 756-761.
14. Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology (Bethesda) 2009; 24: 159-170.
15. Boden G, Ruiz J, Urbain JL, Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol 1996; 271(2 Pt 1): E246-E252.
16. Lee A, Ader M, Bray GA, Bergman RN. Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects. Diabetes 1992; 41: 750-759.
17. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999; 48: 2182-2188.
18. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996; 45: 1044-1050.
19. Kring SI, Werge T, Holst C et al. Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS ONE 2009; 4: e6696.
20. Gibson WT, Ebersole BJ, Bhattacharyya S et al. Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity. Can J Physiol Pharmacol 2004; 82: 426-429.
21. Zhou L, Sutton GM, Rochford JJ et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007; 6: 398-405.
22. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009; 11: 665-679.
23. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998; 22: 619-623.
24. Prasai MJ, George JT, Scott EM. Molecular clocks, type 2 diabetes and cardiovascular disease. Diab Vasc Dis Res 2008; 5: 89-95.
25. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007; 9: 1-24.
26. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010; 13: 635-641.
27. Szczypka MS, Rainey MA, Palmiter RD. Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nat Genet 2000; 25: 102-104.
28. Reinholz J, Skopp O, Breitenstein C, Bohr I, Winterhoff H, Knecht S. Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations. Nutr Metab (Lond) 2008; 5: 35.
29. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with u sual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007; 7: 3.
30. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995; 44: 1349-1355.
31. Li AJ, Wang Q, Dinh TT, Ritter S. Simultaneous silencing of Npy and Dbh expression in hindbrain A1/C1 catecholamine cells suppresses glucoprivic feeding. J Neurosci 2009; 29: 280-287.
32. Ritter S, Dinh TT, Li AJ. Hindbrain catecholamine neurons control multiple glucoregulatory responses. Physiol Behav 2006; 89: 490-500.
33. Meguid MM, Fetissov SO, Varma M et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843-857.
34. Telegdy G, Vermes I. Effect of adrenocortical hormones on activity of the serotoninergic system in limbic structures in rats. Neuroendocrinology 1975; 18: 16-26.
35. Moore KE, Demarest KT, Johnston CA. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc 1980; 39: 2912-2916.
36. Myers BL, Badia P. Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Neurosci Biobehav Rev 1995; 19: 553-571.
37. Weaver JU, Noonan K, Kopelman PG, Coste M. Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol 1990; 32: 641-646.
38. Copinschi G, De Laet MH, Brion JP et al. Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects. Influence of prolonged fasting in obesity. Clin Endocrinol 1978; 9: 15-26.
39. Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998; 68: 1-10.
40. Shimazu T, Noma M, Saito M. Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res 1986; 369: 215-223.
41. Smythe GA, Grunstein HS, Bradshaw JE, Nicholson MV, Compton PJ. Relationships between brain noradrenergic activity and blood glucose. Nature 1984; 308: 65-67.
42. Luo S, Luo J, Cincotta AH. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int 2000; 17: 155-172.
43. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160-166.
44. Cincotta AH, Meier AH, Southern LL. Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab 1989; 33: 305-314.
45. Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 1999; 23: 425-431.
46. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993; 264(2 Pt 1): E285-E293.
47. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992; 48: 248-253.
48. Kamath V, Jones CN, Yip JC et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997; 20: 1697-1701.
49. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000; 23: 1039-1040.
50. Kok P, Roelfsema F, Frolich M et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab 2006; 291: E1038-E1043.
51. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19: 667-670.
52. Pijl H, Ohashi S, Matsuda M et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161.
53. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004; 62: 55-59.
54. Gaziano JM, Cincotta AH, O'Connor CM et al. Randomized clinical trial of quick release-bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33: 1503-1508.
55. Scobie IN, Kesson CM, Ratcliffe JG, MacCuish AC. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus. Clin Endocrinol 1983; 18: 179-185.
56. Atkison PR, Mahon JL, Dupre J et al. Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study. J Autoimmun 1990; 3: 793-799.
57. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
58. US Food and Drug Administration. Cycloset FDA label. Available from URL: Accessed 8 September 2010.